Still, the choice of an insulin regimen for initiation or intensification of therapy is a subjective decision, that should consider the duration of diabetes, symptoms of hyperglycemia, lifestyle, drug therapy, glycaemic status (with patterns of glycaemia, risk of hypoglycemia and glycaemic variability) and patient preference [9]. This evidence concerns the gene INS and Hyperglycemia.